Neuroinvasion by scrapie following inoculation via the skin is independent of migratory Langerhans cells

Citation for published version:

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
J Virol

Publisher Rights Statement:
Copyright © 2005, American Society for Microbiology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Neuroinvasion by Scrapie following Inoculation via the Skin Is Independent of Migratory Langerhans Cells

Joanne Mohan, Moira E. Bruce, and Neil A. Mabbott*
Neuropathogenesis Unit, Institute for Animal Health, Edinburgh, Scotland, United Kingdom

Received 18 June 2004/Accepted 7 September 2004

Many natural transmissible spongiform encephalopathy (TSE) infections are likely to be acquired peripherally, and studies in mice show that skin scarification is an effective means of scrapie transmission. After peripheral exposure, TSE agents usually accumulate in lymphoid tissues before spreading to the brain. The mechanisms of TSE transport to lymphoid tissues are not known. Langerhans cells (LCs) reside in the epidermis and migrate to the draining lymph node after encountering antigen. To investigate the potential role of LCs in scrapie transportation from the skin, we utilized mouse models in which their migration was blocked either due to CD40 ligand deficiency (CD40L<sup>−/−</sup> mice) or after caspase-1 inhibition. We show that the early accumulation of scrapie infectivity in the draining lymph node and subsequent neuroinvasion was not impaired in mice with blocked LC migration. Thus, LCs are not involved in TSE transport from the skin. After intracerebral inoculation with scrapie, wild-type mice and CD40L<sup>−/−</sup> mice develop clinical disease with similar incubation periods. However, after inoculation via skin scarification CD40L<sup>−/−</sup> mice develop disease significantly earlier than do wild-type mice. The shorter incubation period in CD40L<sup>−/−</sup> mice is unexpected and suggests that a CD40L-dependent mechanism is involved in impeding scrapie pathogenesis. In vitro studies demonstrated that LCs have the potential to acquire and degrade protease-resistant prion protein, which is thought to be a component of the infectious agent. Taken together, these data suggest that LCs are not involved in scrapie transport to draining lymphoid tissues but might have the potential to degrade scrapie in the skin.

The transmissible spongiform encephalopathies (TSEs; or prion diseases) are a group of infectious, fatal, neurodegenerative diseases, which affect both animals and humans. During disease, PrP<sup>Sc</sup>, an abnormal, detergent-insoluble, relatively proteinase-resistant isoform of the host glycoprotein PrP<sup>C</sup> (38) accumulates in infected tissues. The deposition of PrP<sup>Sc</sup> within the brains of most TSE-affected hosts is usually accompanied with the development of neuropathological changes, such as vacuolation, gliosis, and neuronal loss. Although the precise nature of the TSE agent is not known, PrP<sup>Sc</sup> accumulates with infectivity in infected tissues and is considered to be a major or possibly the sole component of the infectious agent (44).

Many TSEs, including natural sheep scrapie, bovine spongiform encephalopathy (BSE), chronic wasting disease in mule deer and elk, and variant Creutzfeldt-Jakob disease (vCJD) in humans, are acquired by peripheral exposure. For example, the consumption of BSE-contaminated meat products by humans is most likely responsible for the emergence of vCJD (7, 22). Although many natural TSE infections are likely to be acquired orally, studies in mice show that skin scarification is also an effective means of scrapie transmission (51). This suggests some natural TSE cases might be transmitted through skin lesions in the mouth (3) or through sites of skin trauma during close contact with infected animals. The potential to transmit vCJD in humans iatrogenically during surgical or dental procedures is a current concern.

Early PrP<sup>Sc</sup> accumulation takes place on follicular dendritic cells (FDCs) within germinal centers in lymphoid tissues of patients with vCJD (21), in mule deer with chronic wasting disease (47), in sheep with natural scrapie (55), and in rodents inoculated with scrapie by peripheral routes (6, 33, 37). In mouse scrapie models, mature FDCs are critical for scrapie replication and PrP<sup>Sc</sup> accumulation in lymphoid tissues and, in their absence, neuroinvasion after peripheral challenge is significantly impaired (6, 32, 39, 51). From the lymphoid tissues, scrapie is translocated to the central nervous system (CNS) via peripheral nerves (20, 42).

Scrapie neuroinvasion after inoculation into the skin does not occur through direct uptake by nerves in the skin since highly immunodeficient SCID mice are refractory to scrapie when inoculated by this route (51). These data confirm that after inoculation via the skin, neuroinvasion occurs after accumulation in lymphoid tissues as demonstrated after inoculation by other peripheral routes (6, 34). How TSE agents are initially transported from the site of exposure, such as the gastrointestinal tract or the skin, to the germinal centers in which they replicate is not known. FDCs could directly trap cell-free PrP<sup>Sc</sup> or other agent-associated molecules in a complement-bound complex (28, 31), but it is also possible that mobile cells transport the agent to lymphoid follicles. Several cells have the potential to transport TSE agents, including macrophages and migratory bone marrow-derived dendritic cells (DCs). The evidence that macrophages destroy infectivity and degrade PrP<sup>Sc</sup> makes them an unlikely and inefficient transport candidate (4, 10, 11). Migratory bone marrow-derived DCs are a distinct lineage from tissue-fixed, stroma-derived FDCs, which are not considered to be of hemopoietic origin (14, 25). These DCs continually circulate throughout the host’s tissues and tissue fluids, where they sample antigens and transport them to lymphoid tissues (2). Unlike macrophages, DCs can retain some...
protein antigens in native, nondegraded form (57). A subpopulation of these migratory DCs has been shown to transport intestinally injected PrPSc to mesenteric lymph nodes via the lymph (23), but direct demonstration of their involvement in TSE pathogenesis is lacking.

Langerhans cells (LCs) are a subset of migratory DCs that reside in the epidermis and migrate to the draining lymph node following antigen encounter (2). DCs, including LCs, are considered to provide potential mechanisms for the transmission of some pathogens into the skin such as dengue virus (56), human immunodeficiency virus (45), maedi-visna lentivirus (46), and Venezuelan equine encephalitis virus (35). These characteristics suggested to us that LCs are plausible candidates for scrapie transport from the skin to draining lymph nodes. LCs require a number of stimuli to induce their mobilization out of the skin (2). The CD40-CD40L signaling pathway is just one component in a complex network of stimuli that regulate the migration of antigen-bearing LCs out of the epidermis to the draining lymph node (40). In mice deficient in CD40 ligand (CD40L−/− mice), the number and morphology of LCs in the epidermis is normal, but they fail to migrate from the skin and do not accumulate in the draining lymph node (40). Likewise, caspase-1 plays an important role in the regulation of LC migration, and its specific inhibition blocks LC migration from the epidermis (1). In order to investigate the potential role of LCs in scrapie transportation from skin to draining lymphoid tissues, we studied pathogenesis in models in which the migration of these cells from the epidermis was impaired, either due to CD40L deficiency (40) or to caspase-1 inhibition (1). We used these models to investigate the potential role of LCs in scrapie pathogenesis after inoculation via the skin with doses of scrapie equivalent to and much lower than those previously shown to require amplification in lymphoid tissues prior to neuroinvasion (31, 32, 51).

MATERIALS AND METHODS

Mice. CD40 ligand-deficient (CD40L−/−) mice (58) were bred and maintained on the C57BL/6 background. Age- and sex-matched C57BL/6 mice were used as wild-type control mice in studies with CD40L−/− mice. Another subline of C57BL mice, C57BL/Dk mice, were used in all other studies. All mice were housed under specific-pathogen-free conditions.

Scrapie inoculation. Mice (8 to 12 weeks of age) were inoculated with the ME7 scrapie strain by skin scarification of the medial surface of the right thigh. Briefly, prior to scarification ~1 cm2 of hair covering the scarification site was trimmed by using curved scissors and then removed completely with an electric razor. After 24 h a 23-gauge needle was used to create a 5-mm abrasion in the epidermal layers of the skin at the scarification site. Care was taken to avoid damage to the dermis or drawing blood during scarification. Then, by using a 26-gauge needle, one droplet (~6 µl) of ME7 scrapie mouse brain homogenate containing ca. 105 or 106 50% infectious dose (ID50) units was applied to the abrasion and worked into the site by using sweeping strokes. The scarification site was then sealed with OpSite (Smith & Nephew Medical, Ltd., Hull, United Kingdom) and allowed to dry before the animals were returned to their final holding cages. Where indicated, separate groups of mice were inoculated by intracerebral (i.c.) injection with 20 µl of scrapie mouse brain homogenate containing ca. 104.5 ID50 units as a titer control. After challenge, animals were coded, assessed weekly for signs of clinical disease, and killed at a standard clinical endpoint (17). Scrapie diagnosis was confirmed by histopathologic assessment of TSE vacuolation in the brain. For the construction of lesion profiles, vacuolar changes were scored in nine gray-matter and three white-matter areas of the brain as described previously (18).

Where indicated, some mice were sacrificed 49 days postinoculation, and spleens and inguinal lymph nodes (ILNs) were taken for further analysis. For bioassay of scrapie infectivity, two half spleens were pooled from each group and prepared as 10% (wt/vol) homogenates in physiological saline. Likewise, the ILNs draining the inoculation site were pooled from two mice and prepared as a 10% (wt/vol) homogenate. Groups of 12 C57BL/Dk indicator mice were injected i.c. with 20 µl of each homogenate. The scrapie titer in each sample was determined from the mean incubation period in the assay mice by reference to established dose-incubation period response curves for scrapie-infected spleen tissue.

As caspase inhibitor treatment. Where indicated, prior to inoculation with scrapie by skin scarification, groups of C57BL/Dk mice were pretreated at the shaved inoculation site with 50 µl of 0.4 mM caspase-1 inhibitor II (Ac-YVAD-cmk; Calbiochem, Beeston, United Kingdom). 0.4 mM caspase-3 inhibitor III (Ac-DEVDT-cmk; Calbiochem), or vehicle alone (dimethyl sulfoxide [DMSO]) by using a previously established protocol (1). One hour later, mice were inoculated with scrapie as described above. Care was taken to ensure that the scrapie inoculum was only applied to the pretreated area of skin.

Immunochemical analysis. To monitor FDC status, spleen halves were snap-frozen at the temperature of liquid nitrogen. Serial frozen sections (thickness, 10 µm) were cut on a cryostat, and FDCs were visualized by staining with either the FDC-specific rat monoclonal antiserum FDC-M2 (AMS Biotechnology, Oxon, United Kingdom) or 8C12 monoclonal antiserum to detect CD35 (BD Biosciences Pharmingen, Oxford, United Kingdom). B lymphocytes were detected by using the rat B220 monoclonal antiserum to detect CD45R (Caltag, Towcester, United Kingdom) or biotin-conjugated peanut agglutinin (PNA; Sigma, Poole, United Kingdom) to detect germinal center B lymphocytes. Immunolabeling was carried out with alkaline phosphatase coupled to the avidin-biotin complex (Vector Laboratories, Burlingame, Calif.). Vector Red (Vector Laboratories) was used as a substrate.

For the detection of PrP in the brain, tissues were fixed in periadeptyl alcohol and embedded in paraffin wax. Sections (thickness, 6 µm) were deparaffinized and then pretreated to enhance PrP immunostaining by hydrated autoclaving (15 min, 121°C, hydration) and subsequent immersion in formic acid (98%) for 5 min (37). Sections were then stained with the PrP-specific monoclonal antiserum 6H4 (Prionics, Zurich, Switzerland), and immunolabeling was detected by using hydrogen peroxide coupled to the avidin-biotin complex (Vector Laboratories) with dianisobenzofenazide as a substrate. Glial fibrillary acid protein (GFAP) was detected on adjacent brain sections by using rabbit GFAP-specific antiserum (Dako, Ltd., Ely, United Kingdom), and immunolabeling carried out by using alkaline phosphatase coupled to the avidin-biotin complex by using Vector Red as a substrate. Microglia were detected by staining with biotin-conjugated Lycopersicon esculentum agglutinin (LEA; Sigma), and specific labeling was detected by using hydrogen peroxide coupled to the avidin-biotin complex with dianisobenzofenazide as a substrate.

All sections were counterstained with hematoxylin to distinguish cell nuclei.

Immunoblot detection of PrPSc. Individual spleen fragments or ILNs were prepared as previously described (15). Briefly, before immunoblot analysis, tissue homogenates were treated in the absence or presence of 80 µg of proteinase K (to confirm the presence of PrPSc), electrophoresed through sodium dodecyl sulfate–10 to 20% polyacrylamide gels (Bio-Rad, Hemel Hempstead, United Kingdom) and transferred to nitrocellulose membranes (Bio-Rad) by semidy blotting. PrP was detected with the PrP-specific mouse monoclonal antiserum 6H4 (61). Immunolabeling was carried out with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G antiserum (Jackson Immuno research Laboratories, Inc., West Grove, Pa.), and bound horseradish peroxidase activity was detected with Supersignal West Dura Extended Duration Substrate (Pierce, Chester, United Kingdom).

Cell culture. The XS106 and XS52 cell lines (54, 59) are long-term DC lines established from the epidermis of newborn A/J mice and BALB/c mice, respectively. XS106 cells were expanded and maintained in complete RPMI 1640 (60) supplemented with 0.5 ng of recombinant murine granulocyte colony-stimulating factor (R&D Systems, Abingdon, United Kingdom)/ml and 5% (vol/vol) NS47 fibroblast culture supernatant. XS52 cells were expanded and maintained in complete RPMI 1640 supplemented with 2.0 ng of recombinant murine granulocyte colony-stimulating factor/ml and 10% (vol/vol) NS47 fibroblast culture supernatant/ml. Both cell lines were cultured at 37°C in a 5% CO2-air atmosphere. For scrapie inoculation studies, sterile coverslips were placed in the wells of a 24-well plate (Corning, Buckinghamshire, United Kingdom). Cells (5 × 105 in 1 ml of medium) were seeded into each well. When confluent (ca. 2 × 106 cells per coverslip), each well was then inoculated with 10 µl of 10% (wt/vol) terminal scrapie mouse brain homogenate in complete RPMI (corresponding to 1.0 mg of tissue). Duplicate sets of cultures were inoculated with 10 µl of 10% (wt/vol) uninfected mouse brain homogenate in complete RPMI as a control. The medium was removed after 1 h of incubation at 37°C in a 5% CO2-air atmosphere, and cells in each well were washed extensively with fresh medium by pipetting. The cells were then incubated at 37°C for the times...
indicated before being assayed for PrPSc accumulation by the cell blot procedure (5). Briefly, coverslips were removed, and the cell-containing side was blotted onto polyvinylidene difluoride membranes, treated with proteinase K, denatured with guanidine isothiocyanate, and PrP detected by using the PrP-specific mouse monoclonal antiserum 8H4 (61). Immunolabeling was carried out with horse-radish peroxidase-conjugated goat anti-mouse IgG antiserum (Jackson ImmunoResearch Laboratories), and bound horseradish peroxidase activity was detected with Supersignal West Dura Extended Duration Substrate (Pierce). After exposure, membranes were stained with 0.5 μg of ethidium bromide/ml and observed in UV light to confirm transfer of the cell layer (13). Cell viability was assessed in duplicate sets of cultures by trypan blue dye exclusion, and metabolic activity was measured by using AlamarBlue (Sercotec, Oxford, United Kingdom).

Statistical analysis. Where indicated, the incubation periods are presented as mean (days) ± standard error of the mean. Significant differences between incubation periods in different groups were determined by one-way analysis of variance (ANOVA) with Minitab for Windows software (Minitab, Inc., State College, Pa.).

RESULTS

Effect of caspase-1 inhibition on scrapie pathogenesis. Previous studies have shown that topical treatment with a pharmacological inhibitor of caspase-1 potently blocks LC migration from the skin (1). Therefore, we investigated whether the accumulation of scrapie in the draining lymph node was affected after topical caspase-1 inhibition. Prior to inoculation with scrapie by skin scarification of the medial surface of the right thigh, C57BL/Dk mice were treated at the inoculation site with Ac-YVAD-cmk (a caspase-1 inhibitor) or Ac-DEVD-cmk (a caspase-3 inhibitor) or vehicle alone (DMSO) as controls. That is, the number of animals affected/the total number of animals inoculated. Degrees of significance between the mean incubation periods for each treatment group compared to untreated control mice (None) were determined by ANOVA. Values represent P values, where P ≤ 0.05 was considered significant different.

Effect of CD40L deficiency on scrapie accumulation in lymphoid tissues. We next investigated scrapie pathogenesis in mice with a permanent block in LC migration out of the skin due to a targeted deletion of the CD40L gene (CD40L-/- mice [40]). CD40L-/- mice are incapable of mounting T-cell dependent humoral immune responses, and germinal center development is impaired (58). Therefore, FDC status was first assessed in spleens from C57BL/6 wild-type mice and CD40L-/- mice. Germinal centers containing PNA-binding B lymphocytes were detected in the spleens of all C57BL/6 wild-type mice but not in the spleens of CD40L-/- mice (Fig. 1a). Despite the impaired germinal center formation in the lymphoid tissues of CD40L-/- mice, mature FDC networks surrounded by B lymphocytes (CD45R/B220 positive cells) were detected (Fig. 1b). Expression of the markers FDC-M2 and CD35 by FDCs in spleens of CD40L-/- mice but not in the spleens of CD40L-/- mice. In the present study, ILNs draining the site of inoculation with Ac-YVAD-cmk (a caspase-1 inhibitor) or Ac-DEV-CD-cmk (a caspase-3 inhibitor) or vehicle alone (DMSO) as controls. Therefore, we investigated whether the early accumulation of scrapie in the draining lymphoid tissues was affected by skin scarification of the medial surface of the right thigh.

Effect of caspase-1 inhibition on scrapie pathogenesis. Previous studies have shown that topical treatment with a pharmacological inhibitor of caspase-1 potently blocks LC migration from the skin (1). Therefore, we investigated whether the accumulation of scrapie in the draining lymph node was affected after topical caspase-1 inhibition. Prior to inoculation with scrapie by skin scarification (10^4 ID50 units), C57BL/Dk mice were treated at the inoculation site with Ac-YVAD-cmk, a cell-permeable, irreversible caspase-1 inhibitor (19, 53), according to a previously established protocol (1). This treatment effectively and irreversibly blocks both spontaneous and induced LC migration from the epidermis (1). Control pretreatments included application of Ac-DEVD-cmk, a specific inhibitor of caspase-3 that has little effect on spontaneous and induced LC migration from the epidermis (1). Therefore, we investigated whether the early accumulation of scrapie in the draining lymphoid tissues was affected by skin scarification of the medial surface of the right thigh.

Effect of caspase-1 inhibition on scrapie pathogenesis. Previous studies have shown that topical treatment with a pharmacological inhibitor of caspase-1 potently blocks LC migration from the skin (1). Therefore, we investigated whether the accumulation of scrapie in the draining lymph node was affected after topical caspase-1 inhibition. Prior to inoculation with scrapie by skin scarification (10^4 ID50 units), C57BL/Dk mice were treated at the inoculation site with Ac-YVAD-cmk, a cell-permeable, irreversible caspase-1 inhibitor (19, 53), according to a previously established protocol (1). This treatment effectively and irreversibly blocks both spontaneous and induced LC migration from the epidermis (1). Control pretreatments included application of Ac-DEVD-cmk, a specific inhibitor of caspase-3 that has little effect on spontaneous and induced LC migration from the epidermis (1). Therefore, we investigated whether the early accumulation of scrapie in the draining lymphoid tissues was affected by skin scarification of the medial surface of the right thigh.

Table 1. Treatment of skin with the caspase-1 inhibitor Ac-YVAD-cmk to block LC migration prior to scrapie inoculation by skin scarification does not affect disease susceptibility

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Incidence</th>
<th>Mean incubation period (days) ± SE</th>
<th>Statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>3/3</td>
<td>232 ± 4</td>
<td></td>
</tr>
<tr>
<td>DMSO</td>
<td>1/1</td>
<td>323 ± 4</td>
<td></td>
</tr>
<tr>
<td>Ac-YVAD-cmk</td>
<td>2/2</td>
<td>323 ± 4</td>
<td></td>
</tr>
<tr>
<td>Ac-DEV-cmk</td>
<td>2/2</td>
<td>323 ± 4</td>
<td></td>
</tr>
</tbody>
</table>

* C57BL/Dk mice were inoculated with the ME7 scrapie strain (10^4 ID50 units) by skin scarification of the medial surface of the right thigh.

** Prior to scrapie inoculation mice were pretreated at the shaved inoculation site with Ac-YVAD-cmk (a caspase-1 inhibitor) or Ac-DEV-cmk (a caspase-3 inhibitor) or vehicle alone (DMSO) as controls.

### Table 1. Treatment of skin with the caspase-1 inhibitor Ac-YVAD-cmk to block LC migration prior to scrapie inoculation by skin scarification does not affect disease susceptibility

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Incidence</th>
<th>Mean incubation period (days) ± SE</th>
<th>Statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>3/3</td>
<td>232 ± 4</td>
<td></td>
</tr>
<tr>
<td>DMSO</td>
<td>1/1</td>
<td>323 ± 4</td>
<td></td>
</tr>
<tr>
<td>Ac-YVAD-cmk</td>
<td>2/2</td>
<td>323 ± 4</td>
<td></td>
</tr>
<tr>
<td>Ac-DEV-cmk</td>
<td>2/2</td>
<td>323 ± 4</td>
<td></td>
</tr>
</tbody>
</table>

* C57BL/Dk mice were inoculated with the ME7 scrapie strain (10^4 ID50 units) by skin scarification of the medial surface of the right thigh.

** Prior to scrapie inoculation mice were pretreated at the shaved inoculation site with Ac-YVAD-cmk (a caspase-1 inhibitor) or Ac-DEV-cmk (a caspase-3 inhibitor) or vehicle alone (DMSO) as controls.

### Table 1. Treatment of skin with the caspase-1 inhibitor Ac-YVAD-cmk to block LC migration prior to scrapie inoculation by skin scarification does not affect disease susceptibility

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Incidence</th>
<th>Mean incubation period (days) ± SE</th>
<th>Statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>3/3</td>
<td>232 ± 4</td>
<td></td>
</tr>
<tr>
<td>DMSO</td>
<td>1/1</td>
<td>323 ± 4</td>
<td></td>
</tr>
<tr>
<td>Ac-YVAD-cmk</td>
<td>2/2</td>
<td>323 ± 4</td>
<td></td>
</tr>
<tr>
<td>Ac-DEV-cmk</td>
<td>2/2</td>
<td>323 ± 4</td>
<td></td>
</tr>
</tbody>
</table>

* C57BL/Dk mice were inoculated with the ME7 scrapie strain (10^4 ID50 units) by skin scarification of the medial surface of the right thigh.

** Prior to scrapie inoculation mice were pretreated at the shaved inoculation site with Ac-YVAD-cmk (a caspase-1 inhibitor) or Ac-DEV-cmk (a caspase-3 inhibitor) or vehicle alone (DMSO) as controls.

### Table 1. Treatment of skin with the caspase-1 inhibitor Ac-YVAD-cmk to block LC migration prior to scrapie inoculation by skin scarification does not affect disease susceptibility

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Incidence</th>
<th>Mean incubation period (days) ± SE</th>
<th>Statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>3/3</td>
<td>232 ± 4</td>
<td></td>
</tr>
<tr>
<td>DMSO</td>
<td>1/1</td>
<td>323 ± 4</td>
<td></td>
</tr>
<tr>
<td>Ac-YVAD-cmk</td>
<td>2/2</td>
<td>323 ± 4</td>
<td></td>
</tr>
<tr>
<td>Ac-DEV-cmk</td>
<td>2/2</td>
<td>323 ± 4</td>
<td></td>
</tr>
</tbody>
</table>

* C57BL/Dk mice were inoculated with the ME7 scrapie strain (10^4 ID50 units) by skin scarification of the medial surface of the right thigh.

** Prior to scrapie inoculation mice were pretreated at the shaved inoculation site with Ac-YVAD-cmk (a caspase-1 inhibitor) or Ac-DEV-cmk (a caspase-3 inhibitor) or vehicle alone (DMSO) as controls.

### Table 1. Treatment of skin with the caspase-1 inhibitor Ac-YVAD-cmk to block LC migration prior to scrapie inoculation by skin scarification does not affect disease susceptibility

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Incidence</th>
<th>Mean incubation period (days) ± SE</th>
<th>Statistical analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>3/3</td>
<td>232 ± 4</td>
<td></td>
</tr>
<tr>
<td>DMSO</td>
<td>1/1</td>
<td>323 ± 4</td>
<td></td>
</tr>
<tr>
<td>Ac-YVAD-cmk</td>
<td>2/2</td>
<td>323 ± 4</td>
<td></td>
</tr>
<tr>
<td>Ac-DEV-cmk</td>
<td>2/2</td>
<td>323 ± 4</td>
<td></td>
</tr>
</tbody>
</table>
mice contained high levels of scrapie infectivity (ca. 5.8 log i.c. ID$_{50}$/g). Again, to compare infectivity titers between groups, a standard deviation of ±0.5 log i.c. ID$_{50}$/g was used as a threshold above or below which samples were considered significantly different. Our data suggested that in the absence of efficient LC migration from the skin the early accumulation of scrapie infectivity in the draining ILN was not impaired, since high levels of infectivity were also detected in samples of ILNs from CD40L$^{-/-}$ mice taken 49 days postinoculation (ca. 5.9 log i.c. ID$_{50}$/g).

Only trace levels of infectivity (<2.0 log i.c. ID$_{50}$/g) were detected in pooled spleen samples from the same wild-type mice and CD40L$^{-/-}$ mice taken 49 days postinoculation. However, at the terminal stage of disease, abundant detergent-insoluble, relatively proteinase K-resistant accumulations of disease-specific PrPSc were detected in spleens from wild-type mice (Fig. 2, lanes 2 and 4) and CD40L$^{-/-}$ mice (Fig. 2, lanes 6 and 8). Taken together, these data demonstrate that after inoculation via the skin, infectivity is propagated to the draining lymph node via the lymphatics in an LC-independent manner and subsequently distributed to the spleen, probably via the bloodstream. Since only trace levels of infectivity are measured in the spleen at a time when high levels of infectivity are detected in the draining lymph node, these data suggest that the initial transmission from the skin to local lymphoid tissues does not occur via the bloodstream.

**Susceptibility of CD40L$^{-/-}$ mice to scrapie infection.** When mice were challenged i.c. with a moderate dose of scrapie (10$^{4.5}$ ID$_{50}$ units), wild-type mice and CD40L$^{-/-}$ mice developed clinical signs of scrapie with similar incubation periods of 159 to 165 days (Table 2). Histopathologic analysis of brain tissue from terminally affected wild-type and CD40L$^{-/-}$ mice displayed the characteristic spongiform pathology, disease-specific PrP accumulation, and reactive astrocytes expressing the high levels of GFAP typical of an i.c. inoculation with the ME7 scrapie strain, although microglia activation appeared more pronounced in the brains of CD40L$^{-/-}$ mice (data not shown). However, the severity and distribution of pathological vacuolation in the brain was not significantly different between mouse strains (Fig. 3a). Thus, these data suggest that the CD40L signaling pathway is not involved in the cerebral pathogenesis of the ME7 scrapie strain.

After inoculation with scrapie by skin scarification, CD40L$^{-/-}$ mice developed clinical disease significantly earlier than immunocompetent wild-type mice (Table 2). For example, following inoculation with a moderate dose of scrapie (10$^{4}$ ID$_{50}$ units), all immunocompetent wild-type mice developed clinical signs of scrapie with a mean incubation period of 344 ± 5 days (n = 8). In contrast, CD40L$^{-/-}$ mice developed clinical scrapie 32 days earlier than the wild-type controls, with a mean incubation period of 312 ± 5 days (P ≤ 0.0003, n = 9 [ANOVA]). Characteristic spongiform pathology and disease-
specific PrP accumulations typical of an infection with the ME7 scrapie strain were detected in the brains of all peripherally inoculated wild-type and CD40L<sup>−/−</sup> mice (Fig. 4). Although the activation status of LEA-binding microglia appeared more pronounced in the brains of CD40L<sup>−/−</sup> wild-type mice. After peripheral inoculation with a limiting dose of scrapie (10<sup>3</sup> ID<sub>50</sub> units), CD40L<sup>−/−</sup> mice also developed clinical scrapie sooner than wild-type mice (Fig. 4). Although, the shortened incubation period in CD40L<sup>−/−</sup> mice was unlikely to be attributed to an exaggerated neuropathology in these mice compared to wild-type mice. After peripheral inoculation with a limiting dose of scrapie (10<sup>5</sup> ID<sub>50</sub> units), CD40L<sup>−/−</sup> mice also developed clinical scrapie sooner than wild-type mice (Table 2). Although CD40L<sup>−/−</sup> mice succumbed to scrapie after inoculation with a limiting dose of scrapie with a mean incubation period of 331 ± 6 days (n = 7), 24 days earlier than wild-type mice (355 ± 13 days, n = 8), the difference between the two groups in this instance was not significant (P ≤ 0.075 [ANOVA]). This is most likely a consequence of the wide scatter of incubation periods for the wild-type mice from 336 to 439 days.

**Skin-derived LC-like cells degrade PrP<sub>Sc</sub> in vitro.** A series of long-term DC lines have been generated from murine skin that retain important features of LCs (54, 59). In the present study, we used the skin-derived LC-like cell lines XS106 and XS52. The XS106 cells express moderate levels of Ia molecules, CD40, CD80, and CD86 and are capable of stimulating immune responses after adoptive transfer (54). Monolayers of XS106 cells were inoculated with a suspension of terminally ME7-scrapie infected brain tissue or normal brain tissue (as a control). After 16 h of incubation, culture medium was aspirated, and cells were washed extensively with fresh medium to remove residual inoculum. Fresh medium was then added to the monolayers, and cells were incubated for up to 96 h. The experiment demonstrated that 24 h after inoculation with scrapie, XS106 LC-like cells had acquired and retained high levels of PrP<sub>Sc</sub> (Fig. 5a). No PrP<sub>Sc</sub> accumulations were detected in association with cells exposed to normal brain homogenate as a control (Fig. 5a). As a further control, cell-free coverslips were also exposed to scrapie-infected brain tissue and treated as described above. No PrP<sub>Sc</sub> was detected on scrapie-exposed cell-free coverslips (data not shown), confirming that the PrP<sub>Sc</sub> accumulations detected in Fig. 5a were cell associated. Antigens acquired by DCs usually quickly enter the lysosomal compartment, where they are broken down into peptides for presentation to lymphocytes in association with major histocompatibility complex class II (2). After extended cultivation of XS106 LC-like cells with scrapie (up to 96 h), the level of PrP<sub>Sc</sub> detected in association with these cells appeared to decline (Fig. 5a). No significant effect on cell viability or metabolic activity was observed after exposure of the cells to scrapie-brain homogenate compared to those exposed to normal brain homogenate or medium alone as controls (data not shown). Thus, the reduction in the PrP<sub>Sc</sub> associated with the cultivation of XS106 LC-like cells was unlikely to be due to reduced cell viability.

In contrast to XS106 cells, XS52 cells are extremely “immature” in terms of their phenotype and function and have a poor
capacity to initiate antigen-specific immune responses in living animals (54, 59). In order to confirm that the ability of XS106 LC-like cells to degrade PrPSc was a property of cells with a phenotype typical of LCs and not a property of all in vitro-cultivated cell lines, parallel experiments were performed with the highly immature LC-like cell line XS52 as a negative control. Although these additional experiments demonstrated that, 24 h after inoculation with scrapie, XS52 LC-like cells had acquired high levels of PrPSc (Fig. 5b), after 96 h cultivation the level of PrPSc detected in brains of CD40L−/− mice compared to wild-type mice. All sections were counterstained with hematoxylin (blue). Magnification, ×100.

FIG. 4. Histological analysis of brain tissue from terminally scrapie-infected C57BL/6 wild-type (WT; left panels) and CD40L−/− mice (right panels) inoculated with scrapie by skin scarification. Large PrP accumulations (upper row; brown), reactive astrocytes expressing high levels of GFAP (second row; red), and spongiform pathology (hematoxylin and eosin; third row) were detected in the hippocampi of all mice that developed clinical signs of scrapie. Analysis of LEA-binding microglia (bottom row; brown) suggested that their activation was more pronounced in brains of CD40L−/− mice compared to wild-type mice. All sections were counterstained with hematoxylin (blue). Magnification, ×100.

FIG. 5. Skin-derived LC-like cells degrade PrPSc in vitro. Monolayers of XS106 LC-like cells (a) or the highly immature cell line XS52 (b) were exposed to 10 μL of 10% scrapie-infected brain homogenate (scrapie) for 16 h. Duplicate sets of cultures were exposed to 10 μL of 10% uninfected normal brain homogenate (NBr) as a control. Monolayers were then washed to remove residual homogenate and incubated for the times indicated at 37°C in a 5% CO2-air atmosphere. Levels of PrPSc associated with the cells were determined by cell blotting (5). Treatment of membranes in the presence (+) or absence (−) of proteinase K (PK) prior to immunostaining is indicated.

**DISCUSSION**

In order to investigate the potential role of LCs in scrapie transportation from the skin to the draining lymph node, we utilized mouse models in which the migration of LCs from the skin was blocked (1, 40). We show that pharmacological blockade of LC migration (1) by treatment with an irreversible inhibitor of caspase-1 prior to inoculation with scrapie through the skin did not impair the early accumulation of infectivity in draining lymphoid tissue or delay subsequent neuroinvasion. The migration of LCs from the skin is also blocked in CD40L−/−/H11002 mice (40). The early accumulation of infectivity in draining lymphoid tissues of these mice was likewise not impaired in the absence of LC migration from the skin. Together, these data suggest that LCs are not involved in TSE transport from the skin to lymphoid tissue. When wild-type mice and CD40L−/−/H11002 mice were challenged with scrapie directly into the CNS, both strains of mice developed clinical signs of scrapie with similar incubation periods and exhibited similar CNS pathology. In contrast, after inoculation via skin scarification the disease incubation period was shorter in CD40L−/−/H11002 mice than in wild-type mice. The shortened disease incubation period in CD40L−/−/H11002 mice was unexpected and demonstrates that a CD40L-dependent process involved in impeding scrapie neuroinvasion was disrupted due to CD40L deficiency. Since DCs can process and degrade PrPSc in vitro (30), these data suggested to us that LCs might degrade scrapie in the skin. To address this, we exposed an epidermis-derived LC-like cell line (59) to scrapie in vitro. Our data suggest that in vitro-cultivated LCs are likewise able to acquire and degrade PrPSc. Taken
together, our studies suggest that LCs are not involved in scrapie transport to draining lymphoid tissue. However, these cells might have the potential to acquire and degrade scrapie in the skin.

TSE transport mechanisms from the site of exposure to the germinal centers in which they replicate are not known. We considered transport in association with migratory bone marrow-derived DCs a credible candidate mechanism since these cells sample antigens in the periphery and transport them to lymphoid tissues (2). DCs can also retain some protein antigens in native, nondegraded form (57). Recent research has demonstrated that bone marrow-derived DCs can acquire PrPSc in vitro (23, 30) and that a subpopulation of migratory DCs has the potential to transport intestinally injected PrPSc to mesenteric lymph nodes via the lymph (23). Others have shown that the prion protein fragment PrP106-126 is a chemoattractant for monocyte-derived DCs (24). Despite these observations, direct demonstration of the involvement of DCs in the initial delivery of TSE agents to lymphoid tissues is lacking. Studies by Oldstone et al. (41) have suggested CD11c+ DCs are not involved in peripheral TSE pathogenesis. However, in that study mice were inoculated with high doses of scrapie, which have been shown consistently to bypass the need for replication in lymphoid tissues in the same RML scrapie model (43) and our own ME7 scrapie model (16). Here we investigated the potential role of LCs in scrapie pathogenesis after inoculation via the skin with doses of ME7 scrapie equivalent to (10^3 ID50 units) and much lower (10^3 ID50 units) than those we have previously shown to require amplification in lymphoid tissues prior to neuroinvasion (31, 32, 51).

The cytokines interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNF-α) play key roles in regulating the migration of LCs from the epidermis to the draining lymph node (12, 49). LC migration from the epidermis is blocked following specific inhibition of either of these cytokines (12). IL-1β is synthesized as an inactive 31-kDa precursor that is cleaved to release the active 17-kDa IL-1β molecule by the cysteine protease caspase-1 (52). In mice deficient in caspase-1 LC migration from the skin is impaired (1). Furthermore, treatment of skin with Ac-YVAD-cmk, an irreversible inhibitor of caspase-1 (19, 53), potently blocks both spontaneous and induced LC migration from the skin (1). Our data show that blockade of LC migration from the epidermis through treatment with Ac-YVAD-cmk prior to inoculation with scrapie did not affect the early accumulation of infectivity in draining ILNs since equally high levels were detected in tissues from both control and treated mice.

Treatment of mice with Ac-YVAD-cmk blocks induced LC migration from the skin by ca. 67% (1). Thus, the possibility that the magnitude of the Ac-YVAD-cmk-mediated inhibition of LC migration was insufficient to observe a measurable effect on pathogenesis deserves consideration. However, this hypothesis relies on the assumption that the 67% reduction in LC migration correlates directly to a 67% reduction in scrapie delivery. Our studies suggest that only a small subpopulation of intestinal DCs (0.5 to 5%) acquire and transport detectable levels of PrPSc from the gut lumen (23). Thus, it is possible that the majority of LC subpopulations, if involved in scrapie transportation, may be retained within the 67% that cannot migrate from the epidermis after Ac-YVAD-cmk treatment. After peripheral inoculation, it is likely that a portion of the inoculum is destroyed by the actions of phagocytic cells before it has the opportunity to begin replication in association with FDCs. The effects of this on pathogenesis are likely to be dose dependent, with small doses being more easily destroyed than higher doses, in which a greater portion would be retained. If a 67% reduction in LC migration did correlate directly to a 67% reduction in the initial scrapie delivery, it is possible that a further fraction may be degraded once it reached the draining lymph node, further reducing the inoculum titer.

With the above points in mind we are confident that the effects of Ac-YVAD-cmk-treatment on LC migration would be sufficient to cause a measurable effect on scrapie pathogenesis if these cells were involved. However, to further address this important issue, a mouse model was used in which LC migration from the skin is permanently blocked. In CD40L−/− mice, the number and morphology of LCs in the epidermis was normal but they did not migrate from the skin after stimulation (40). The defect in LC migration in CD40L−/− mice was associated with defective TNF-α production in the skin (40). When animals were inoculated with scrapie via the skin, high levels of infectivity were also detected within the ILNs of wild-type and CD40L−/− mice 49 days postinoculation. Thus, the early accumulation of scrapie in the draining lymphoid tissue was not impaired in mice whose LCs cannot migrate out of the epidermis. Therefore, these two approaches together suggest that the initial transportation of scrapie from the skin to draining lymphoid tissue occurs through an LC-independent mechanism.

The time point at which the tissues were assayed for infectivity accumulation is critical. If scrapie titers were to peak much sooner than the time they are analyzed it may not be possible to demonstrate a reduced early accumulation in mice with blocked LC migration since sufficient time may have been provided for a reduced scrapie dose to reach peak levels before analysis. Our unpublished observations suggest that after inoculation with scrapie by skin scarification the infectivity levels in the draining ILN begin to peak around 49 days postinoculation and subsequently plateau. If the delivery of scrapie infectivity to the draining lymph node was reduced in the absence of migratory LCs, these data suggest that it would have been possible to demonstrate a reduced accumulation of infectivity in draining ILNs 49 days after inoculation since infectivity levels in tissues from control mice would only just have started to approach peak levels.

Every effort was taken at the time of scarification to avoid causing damage to the dermis or drawing blood to prevent the leakage of infectivity into the bloodstream during inoculation. If scrapie infectivity had leached into the bloodstream, a need for LCs in transportation to lymphoid tissues would obviously have been bypassed. Analysis of spleen tissue 49 days postinoculation failed to detect infectivity in tissues collected from the same wild-type and CD40L−/− mice. These data therefore suggest that the initial transmission of scrapie from the skin to lymphoid tissues does not occur via the bloodstream, which would have resulted in a widespread dissemination of infectivity throughout the lymphoid system. Spleen tissue collected for immunoblot analysis from terminally affected wild-type and CD40L−/− mice detected large accumulations of PrPSc. Therefore, following inoculation via the skin, infectivity is first prop-
agated to the draining lymph node via the lymphatics in an LC-independent manner and subsequently distributed to the spleen, probably via the bloodstream.

Mice deficient in CD40L are incapable of mounting T-lymphocyte-dependent humoral immune responses (58). Although mature FDC networks surrounded by B cells were detected in the spleens of CD40L−/− mice, germinal centers containing PNA-binding B lymphocytes were absent. After inoculation by skin scarification CD40L−/− mice accumulated levels of PrPSc and infectivity in their lymphoid tissues comparable to wild-type mice, despite an absence of germinal centers. Thus, the absence of PNA-positive germinal centers in CD40L−/− mice does not affect the ability of their lymphoid tissues to accumulate PrPSc and infectivity after exposure to the ME7 scrapie strain. These data are consistent with previous studies utilizing IL-6−/− mice that also have diminished germinal centers but mature FDC networks in the spleen (29). After peripheral inoculation with ME7 scrapie, spleens of IL-6−/− mice accumulated levels of PrPSc and scrapie infectivity comparable to those in the spleens of wild-type mice and maintained these levels for the duration of the disease (33). Since deficiencies in T lymphocytes (26, 27) or circulating immunoglobulins (28) do not affect scrapie pathogenesis, it is likewise unlikely that the impaired T-lymphocyte-dependent humoral immune responses in CD40L−/− mice (58) affect pathogenesis.

Congruent with the observation that the early accumulation of scrapie infectivity in lymphoid tissues was not impaired in the absence of LC migration, further studies demonstrated that scrapie susceptibility was not reduced in mice with blocked LC migration. When challenged with skin scarification, CD40L−/− mice succumbed to clinical disease with a significantly shorter incubation period than wild-type mice (Table 2). The shortened incubation period in CD40L−/− mice was unexpected since a similar affect on scrapie pathogenesis was not observed after inhibition of LC migration by topical treatment with a caspase-1 inhibitor (Table 1). CD40 signaling on neurons has been shown to play a physiological role in promoting neuronal maintenance and survival (50). Thus, the shortened scrapie incubation period observed in peripherally inoculated CD40L−/− mice might have been due to an increased susceptibility of CD40L-deficient neurons to TSE-induced neurodegeneration. After inoculation of wild-type and CD40L−/− mice with scrapie directly into the CNS (i.c. injection), all mice developed clinical disease with similar incubation periods. Furthermore, the pathological targeting of the TSE-induced vacuolation (Fig. 3), PrPSc accumulation, or gliosis within the brain was not significantly different between mouse strains, although microglia activation appeared to be more pronounced in CD40L−/− mice. Despite this apparent increase in microglia activation, the magnitude and distribution of the disease-specific vacuolation in 12 different brain regions were similar between CD40L−/− and wild-type mice. These data therefore demonstrate that the CD40-CD40L signaling pathway does not play a critical role in the cerebral pathogenesis of ME7 scrapie. Therefore, the shortened incubation period observed in peripherally inoculated CD40L−/− mice was most likely due to the absence of a CD40L-dependent mechanism in the periphery, which may be involved in impeding scrapie pathogenesis. It may also be possible that CD40L deficiency affects the permeability of peripheral neurons to TSEs influencing uptake and neuroinvasion.

In contrast to data described in the present study, a recent report suggests the CD40-CD40L signaling pathway is involved in the development and progression of CNS disease after inoculation with the 139A scrapie strain (8). In that study, CD40L−/− mice inoculated with 139A scrapie directly into the CNS (i.c. injection) succumbed to disease 40 days earlier than did wild-type control mice. Congruent with the findings in our study, no significant differences in the extent of disease-specific PrP-deposition or GFAP-expressing astrocytes were detected in the brains of CD40L−/− and wild-type mice, although microglia activation appeared to be more pronounced in CD40L−/− mice. However, the magnitude of the disease-associated vacuolation detected in the brains of CD40L−/− mice was also more pronounced than in wild-type mice (8). This is in contrast to data from our studies in which the magnitude and distribution of the pathological targeting of the vacuolation in CD40L−/− mice were remarkably similar to the findings in wild-type mice after inoculation either directly into the CNS (i.c.) or via the skin (Fig. 3). In wild-type mice the distribution and magnitude of the pathological targeting of the vacuolation within the brain differs significantly between the 139A and ME7 scrapie strains: for example, the 139A scrapie strain induces stronger vacuolation in white matter. Therefore, these two studies, considered together, suggest that it is possible that the effects of CD40L on scrapie pathogenesis within the brain are strain dependent.

CD40-CD40L interactions have a diverse range of activities within the immune system, and further studies are necessary to determine the precise effect of the blockade of this signaling pathway on peripheral pathogenesis of ME7 scrapie. Apart from a lack of PNA-binding germinal centers (58), there was little evidence of disrupted lymphoid architecture in the lymphoid tissues of CD40L−/− mice. Thus, the reduced incubation period was unlikely to be due to effects on lymphoid architecture, such as the repositioning of splenic FDCs in close association with peripheral nerves as recently shown in mice deficient in the CXCR5 chemokine receptor (42). CD40-CD40L interactions provide important signals for optimal macrophage activation, and CD40L deficiency increases susceptibility to certain intracellular pathogens (9, 36, 48). For example, macrophages from Leishmania amazonensis-infected CD40L−/− mice contain high parasite burdens and are unable to effectively control the parasitemia (48). Since previous studies suggest that macrophages may sequester and destroy scrapie infectivity (4, 10, 11), it is reasonable to speculate that in the absence of CD40-CD40L signaling in CD40L−/− mice the clearance of scrapie infectivity by cells such as macrophages is likewise inhibited. For example, studies from Prinz et al. (43) demonstrate that, in the absence of TNF receptor 1 signaling, scrapie replication can occur in macrophages. Following uptake by DCs, antigens rapidly enter the lysosomal compartment, where they are broken down into peptides for presentation to lymphocytes in association with major histocompatibility complex class II (2). A recent study suggests that DCs may handle TSE agents in a similar manner, since bone marrow-derived DCs are able to process and degrade PrPSc after in vitro exposure (30). Our studies also show that in vitro-cultivated XS106 LC-like cells have the potential to acquire and degrade
PrPSc. Another interpretation of these observations may be that, after the uptake of PrPSc by XSI06 LC-like cells, subsequent processing and/or catabolism of PrPSc masks the 8H4 epitope. However, whatever the effects of XSI06 cells on PrPSc were, further experiments confirmed that this was not a property of all in vitro-cultivated cell lines since the highly immature cell line X552 was unable to degrade PrPSc. Thus, these data suggest that highly efficient antigen-processing LCs might be impeded in processing scrapie in CD40L-deficient mice. Inhibition of CD40L-dependent clearance mechanisms might allow infectivity to accumulate earlier in draining lymphoid tissue, shortening the disease incubation period. Treatments that modulate this CD40L-dependent protective mechanism might provide an effective therapeutic strategy for early intervention in TSE pathogenesis.

The data presented here suggest that LCs are not involved in the transportation of scrapie from the skin to lymphoid tissues. However, these data do suggest that a CD40-CD40L-dependent mechanism is involved in impeding scrapie neuroinvasion. The precise mechanism by which scrapie infectivity is transported from the skin to lymphoid tissues remains to be identified. Since macrophages are most likely involved in the degradation of infectivity (4, 10, 11), it is possible that scrapie infectivity is transported in a cell-free manner. Soon after eradication of infectivity (4, 10, 11), it is possible that scrapie infectivity (4, 10, 11), it is possible that scrapie infectivity is transported in a cell-free manner. Soon after eradication of infectivity (4, 10, 11), it is possible that scrapie infectivity is transported in a cell-free manner. Soon after eradication of infectivity (4, 10, 11), it is possible that scrapie infectivity is transported in a cell-free manner. Soon after eradication of infectivity (4, 10, 11), it is possible that scrapie infectivity is transported in a cell-free manner. Soon after eradication of infectivity (4, 10, 11), it is possible that scrapie infectivity is transported in a cell-free manner. Soon after eradication of infectivity (4, 10, 11), it is possible that scrapie infectivity is transported in a cell-free manner. Soon after eradication of infectivity (4, 10, 11), it is possible that scrapie infectivity is transported in a cell-free manner. Soon after eradication of infectivity (4, 10, 11), it is possible that scrapie infectivity is transported in a cell-free manner.